Browse > Article

Immunoadjuvanticity of Novel CpG ODN (Oligodeoxynucleotide)  

Park, Su-Jung (Department of Microbiology, Yonsei University Wonju College of Medicine)
Cho, Hyeon-Cheol (Department of Microbiology, Yonsei University Wonju College of Medicine)
Bae, Keum-Seok (Department of General Surgery, Yonsei University Wonju College of Medicine)
Kim, Soo-Ki (Department of Microbiology, Yonsei University Wonju College of Medicine)
Publication Information
Molecular & Cellular Toxicology / v.3, no.1, 2007 , pp. 46-52 More about this Journal
Abstract
In the course of novel TLR (Toll like receptor) 9 ligand, we found novel CpG ODN (Oligodeoxynucleotide) was active in augmenting antibody in mice. However, immune mechanism of new CpG ODNs is unclear. To clarify this, we examined immunoadjuvanticity by employing in vitro and in vivo immune profiles. In brief, in vitro treatment of novel CpG ODN upregulated the expression of TNF-$\alpha$, IL-6, and IL-12 mRNA in macrophages as well as that of IFN-$gamma$ mPNA in mouse splenocytes. In parallel, in vivo injection of novel CpG ODN directly activates macrophages and splenocytess, consequently upregulating MHC class II and CD86. Finally, we demonstrated anti-HBs antibody augmentation of novel CpG ODN. Collectively, this data indicates that novel CpG ODN is immunoadjuvant armed with Th1 typed immune machinery.
Keywords
CpG ODN (Oligodeoxynucleotide); Immunoadjuvanticity TLR (Toll like receptor); Th1 (T helper 1);
Citations & Related Records

Times Cited By Web Of Science : 3  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 Cooper, C. L. et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22:3136-3143 (2004)   DOI   ScienceOn
2 Roberts, T. L., Sweet, M. J., Hume, D. A. & Stacey, K. J. Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioatemodified oligonucleotides. J. Immunol. 174:605-608 (2005)   DOI
3 Bhattacharjee, R. N. & Akira, S. Modifying toll-like receptor 9 signaling for therapeutic use. Mini Reviews in Medicinal Chemistry 6:287-291 (2006)   DOI   ScienceOn
4 Link, B. K. et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29: 558-568 (2006)   DOI
5 Krieg, A. M. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochimica et Biophysica Acta 1489:107-116 (1999)   DOI   ScienceOn
6 Chuang, T. H. et al. Toll-like receptor 9 mediates CpG-DNA signaling. Journal of Leukocyte Biology 71:538-544 (2002)
7 Carpentier, A. et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncology 8:60-66 (2006)   DOI   ScienceOn
8 Becker, Y. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications. Anticancer research 26:1113-1134 (2006)
9 Verthelyi, D. & Klinman, D. M. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clinical Immunology Orlando, Fla 109:64-71 (2003)   DOI   ScienceOn
10 Mutwiri, G. K., Nichani, A. K., Babiuk, S. & Babiuk, L. A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J. Control Release 97:1-17 (2004)   DOI   ScienceOn
11 Dittmer, U. & Olbrich, A. R. Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Current Opinion in Microbiology 6:472-477 (2003)   DOI   ScienceOn
12 Carpentier, A. F., Auf, G. & Delattre, J. Y. CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma. Front Biosci. 8:e115-127 (2003)   DOI